Respiratory illnesses on the rise across Pittsburgh area, health experts say

CDC and local Allegheny County data through Dec. 20 show respiratory illnesses—especially influenza—rising nationally and across the Pittsburgh area, with UPMC reporting a three-week surge in flu, COVID-19 and RSV and a faster, earlier flu wave than last year. Clinicians note more severe cases among the elderly and patients with comorbidities and cite lower vaccination uptake as a contributing factor, signaling elevated near-term hospital utilization, testing demand and potential workforce absenteeism.

Analysis

Market structure: Short-term winners are diagnostic & vaccine/antiviral suppliers (Abbott ABT, Quidel QDEL, Pfizer PFE, Moderna MRNA, GSK GSK) as test volumes, Paxlovid/flu antivirals and booster uptake rise; hospitals see volume upside but face margin compression from staffing and supply costs. Losers include national insurers (UNH, CI) through higher claim frequency and regional hospital credits if occupancy spikes >85% for multiple weeks. Expect pricing power for rapid tests and antivirals via volume (20–50% weekly sales lift possible for test-makers) but limited pricing upside for vaccines in the US due to procurement dynamics.

Risk assessment: Tail risks include emergence of a vaccine-evading strain or a supply shortfall of Paxlovid leading to emergency government purchasing and volatile pricing — plausible within 1–3 months and could swing revenues ±30% for targeted drugmakers. Immediate (days): test demand and ED traffic; short-term (weeks–months): quarterly revenue/claims impact; long-term (quarters–years): durable change in vaccination rates and public health policy. Hidden dependencies include school closures and CDC guidance which can amplify hospital load; key catalyst thresholds: CDC hospitalization rate >20% above last-season peak or test-positivity >10% sustained 2 weeks.

Trade implications: Favor concentrated, short-duration longs in ABT (testing) and QDEL (rapid tests) and selective exposure to PFE/MRNA for antivirals/vaccine upside; employ call spreads to control cost and IV risk. Use relative value: long ABT/short UNH to capture provider revenue vs insurer margin squeeze over 1–3 months. Avoid large directional exposure to hospital operators beyond tactical 4–8 week windows due to staffing inflation.

Contrarian angles: Consensus underestimates upside in diagnostic earnings — early-season surges historically produced 8–20% quarterly beats for test makers; market may overpay hospital operational leverage while underpricing insurer margin pressure. Unintended consequence: aggressive short-term buying of antivirals/tests could trigger inventory shortages and temporary government price negotiation, capping upside; therefore prefer conditional scaling and options overlays.

Key Decisions for Investors

• Establish a 2–3% long position in Abbott Laboratories (ABT) within 7 trading days to capture a projected 10–15% revenue-driven share move over 4–8 weeks; size with a hard stop-loss at -6% and a take-profit tranche at +12%.
• Buy a 1–1.5% notional position in Quidel (QDEL) via a 2-month call spread (buy ATM, sell 20% OTM) to limit premium outlay; target +20% on spread exit within 4–6 weeks if CDC test-positivity rises above 10% for two consecutive weeks, max loss = premium paid (~1% risk).
• Initiate a 1.5% long PFE vs 1.5% short UNH pair trade (equal notional) for 3–6 months to capture antiviral/vaccine revenue upside against expected insurer margin pressure; unwind if the spread narrows by 6% or if UNH reports claim trends better-than-expected in next 60 days.
• Avoid adding >1% direct long exposure to hospital operators (e.g., HCA) until Q1 2026; instead reduce high-yield regional hospital credit exposure by 50% if local hospital occupancy exceeds 90% for two consecutive weeks to protect against covenant/credit stress.
• Trigger rule: Monitor CDC weekly hospitalization rate and state-level test-positivity; if hospitalization rate >20% above last-season peak or test-positivity >10% for 2 weeks, scale ABT/QDEL positions up by +1% each within 5 trading days and convert 50% of position gains to cash.